

83. **Hutterer GC, Patard J-J, Colombel M, et al.** Cyto-reductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. *Cancer*. 2007; 110(11): 2428–2433. doi:10.1002/cncr.23054.
84. **Krambeck AE, Leibovich BC, Lohse CM, et al.** The Role of Nephron Sparing Surgery for Metastatic (pM1) Renal Cell Carcinoma. *J Urol*. 2006; 176(5): 1990–1995. doi:10.1016/j.juro.2006. 07. 015.
85. **Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED.** Cyto-reductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis. *J Urol*. 2004; 171(3): 1071–1076. doi:10.1097/01.ju.0000110610.61545.ae.
86. **Chen J, He Q, Liu W, Li Y, Zhuang W.** The Effect of Cyto-reductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma. *Clin Interv Aging*. 2020; Volume 15: 431–439. doi:10.2147/CIA.S243902.
87. **Zlatev DV, Ozambela M, Salari K, et al.** Trends and morbidity for minimally invasive versus open cyto-reductive nephrectomy in the management of metastatic renal cell carcinoma. *J Clin Oncol*. 2018; 36(6_suppl): 632–632. doi:10.1200/JCO.2018. 36. 6_suppl.632.
88. **Rabets JC, Kaouk J, Fergany A, et al.** Laparoscopic versus open cyto-reductive nephrectomy for metastatic renal cell carcinoma. *Urology*. 2004; 64(5): 930–934. doi:10.1016/j.urology.2004. 06. 052.
89. **Eisenberg MS, Meng MV, Master VA, et al.** Laparoscopic versus Open Cyto-reductive Nephrectomy in Advanced Renal-Cell Carcinoma. *J Endourol*. 2006; 20(7): 504–508. doi:10.1089/end.2006. 20. 504.
90. **Ganeshappa A, Sundaram C, Lerner MA, Gardner TA.** Role of the Laparoscopic Approach to Cyto-reductive Nephrectomy in Metastatic Renal-Cell Carcinoma: Does Size Matter? *J Endourol*. 2010; 24(8): 1289–1292. doi:10.1089/end.2009.0401.
91. **Matin SF, Madsen LT, Wood CG.** Laparoscopic cyto-reductive nephrectomy: The M. D. Anderson Cancer Center experience. *Urology*. 2006; 68(3): 528–532. doi:10.1016/j.urology.2006. 03. 076.
92. **Margulis V, Matin SF, Tannir N, et al.** Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cyto-reductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. *J Urol*. 2008; 180(1): 94–98. doi:10.1016/j.juro.2008. 03. 047.
93. **Jackson BL, Fowler S, Williams ST.** Perioperative outcomes of cyto-reductive nephrectomy in the UK in 2012. *BJU Int*. 2015; 116(6): 905–910. doi:10.1111/bju.12890.
94. **Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, et al.** Minimally invasive cyto-reductive nephrectomy: a multi-institutional experience. *World J Urol*. 2016; 34(12): 1651–1656. doi:10.1007/s00345-016-1827-1.
95. **Zhao K, Kim E, Vetter J, et al.** Laparoscopic cyto-reductive nephrectomy is associated with significantly improved survival compared with open cyto-reductive nephrectomy or targeted therapy alone. *Mol Clin Oncol*. 2020; 13(6): 1–1. doi:10.3892/mco.2020.2141.
96. **Abel EJ, Spiess PE, Margulis V, et al.** Cyto-reductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. *J Urol*. 2017; 198(2): 281–288. doi:10.1016/j.juro.2017. 03. 011.
97. **Miyake H, Sugiyama T, Aki R, et al.** Oncological outcomes after cyto-reductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus. *Int J Clin Oncol*. 2018; 23(3): 553–558. doi:10.1007/s10147-017-1232-9.
98. **Kwon T, Lee J-L, You D, et al.** Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy. *J Surg Oncol*. 2014; 110(2): 145–150. doi:10.1002/jso.23612.
99. **Kroeger N, Pantuck AJ, Wells JC, et al.** Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. *Eur Urol*. 2015; 68(3): 506–515. doi:10.1016/j.eururo.2014. 11. 054.
100. **Gershman B, Thompson RH, Moreira DM, et al.** Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cyto-reductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. *J Urol*. 2017; 197(3 Part 1): 574–579. doi:10.1016/j.juro.2016. 09. 074.